Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 17Leukemia 12Breast Neoplasms 12Prostatic Neoplasms 10Neoplasm Metastasis 8Recurrence 6Pancreatic Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Melanoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Philadelphia Chromosome 4Multiple Myeloma 4Lymphoma 4Burkitt Lymphoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Ovarian Neoplasms 3Glioma 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neuroblastoma 2Leukemia, Myelomonocytic, Chronic 2

Interventions

imetelstat 1Thalidomide 1Irinotecan 1GRN163L peptide 1Everolimus 1Dasatinib 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brain Stem Neoplasms × Dasatinib × Clear all
NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
CNS

Glioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡